Pregnenolone methyl ether

Drug Profile

Pregnenolone methyl ether

Alternative Names: 3-methoxy-pregnenolone - Mapreg; MAP-4343

Latest Information Update: 22 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mapreg
  • Class Steroids
  • Mechanism of Action Microtubule-associated protein stimulants; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal cord injuries
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Brain injuries; Spinal cord injuries
  • Preclinical Depressive disorders

Most Recent Events

  • 22 Apr 2016 Pregnenolone methyl ether is still in phase I trials for Spinal cord injuries and in preclinical trials for Depressive disorders in France
  • 22 Apr 2016 Chemical structure information added
  • 22 Apr 2016 Phase-I clinical trials in Brain injuries in France (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top